Table 3.
Clinical characteristics of 75 ACA+ (>74
| Variable | Anti-FOXE3p53-62 | P-value | |
|---|---|---|---|
| Positive (n = 40) | Negative (n = 35) | ||
| Female, n (%) | 38 (95.0) | 33 (94.3) | 1.000a |
| Age at diagnosis, years | 37.4 (14.2) | 41.5 (13.0) | 0.217b |
| Disease duration, years | 20.3 (11.9) | 16.2 (8.5) | 0.151b |
| Disease subtype, limited, n (%) | 37 (92.5) | 33 (94.3) | 0.757a |
| Anti-Ap1-17 IgG, µg/ml | 252.50 (954.00) | 161.00 (313.00) | 0.807b |
| Anti-Ap17-30 IgG, µg/ml | 9.63 (7.00) | 5.23 (7.20) | <0.0001b |
| mRss | 3.70 (4.20) | 4.10 (8.40) | 0.533b |
| FVC, % of predicted | 110.6 (17.0) | 103.7 (20.6) | 0.201b |
| DLCO, % of predicted | 76.2 (24.0) | 76.6 (24.6) | 0.727b |
| sPAP, mm Hg | 29.00 (14.20) | 26.20 (8.20) | 0.510b |
| ILD, n (%) | 8 (20.0) | 5 (15.2) | 0.590 a |
| PAH, n (%) | 5 (12.5) | 3 (8.6) | 0.719a |
| Disease severity score | 5.30 (2.70) | 5.00 (2.30) | 0.570b |
| Disease activity index | 0.91 (0.91) | 1.61 (1.61) | 0.038b |
| Disease activity index domains | |||
| mRss >14 (0.0, 1.0) | 0.02 (0.16) | 0.03 (0.17) | 0.980 |
| Scleredema (0.0, 0.5) | 0.11 (0.21) | 0.11 (0.21) | 0.971 |
| Skin (0.0, 2.0) | 0.05 (0.30) | 0.10 (0.50) | 0.481 |
| Digital necrosis (0.0, 0.5) | 0.07 (0.18) | 0.04 (0.14) | 0.396 |
| Vascular (0.0, 0.5) | 0.06 (0.16) | 0.06 (0.16) | 0.887 |
| Arthritis (0.0, 0.5) | 0.07 (0.20) | 0.06 (0.16) | 0.652 |
| DLCO <80% of predicted (0.0, 0.5) | 0.26 (0.25) | 0.20 (0.25) | 0.282 |
| Heart/lung function (0.0, 2.0) | 0.05 (0.31) | 0.40 (0.81) | 0.015 |
| ESR >30 mm/h (0.0, 1.5) | 0.18 (0.50) | 0.30 (0.60) | 0.380 |
| Low C3 or C4 (0.0, 1.0) | 0.05 (0.22) | 0.31 (0.50) | 0.003 |
Values are presented as mean (SD) unless otherwise indicated. aChi-squared test; bMann-Whitney U-test; a P-value <0.05 was considered significant. SSc, systemic sclerosis; ACA, anti-centromere-associated protein antibodies; mRss, modified Rodnan skin score; FVC, forced vital capacity; DLCO, diffusing lung capacity for carbon monoxide; sPAP, systolic pulmonary arterial pressure; ILD, interstitial lung disease assessed by high resolution computed tomography; PAH, pulmonary arterial hypertension (sPAP >35 mm Hg); ESR, erythrocyte sedimentation rate in the first hour. Cardiac involvement was evaluated by electrocardiography, echocardiography and physical examination.